Consensus Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Market Closed - NYSE 01:30:00 20/10/2026 am IST			5-day change	1st Jan Change
2.190 ^USD	+0.92%		-17.67%	-20.36%

08/10	Perspective Therapeutics, Inc. Receives Fast Track Designation for PSV359 for Treatment of Adult Patients with Locally Advanced Unresectable And/Or Metastatic FAP-Positive Solitary Fibrous Tumors	CI
08/10	Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell	MT

Evolution of the Average Target: Perspective Therapeutics, Inc.

Evolution of the Target Price: Perspective Therapeutics, Inc.

Changes in Analyst Recommendations: Perspective Therapeutics, Inc.

ee273bd6021567bd1396a.lBo76dpi7RnVMecQydNuOtq9kkqJoaNrPGYVHjuDEc8.oXBko4NSjGm7AZ1Vp4UZC7TOwn2k2MxeRiNfJ1PrZKDidAOIhRrVIJNTsg~0173067d71c8fa0fdaf56adefd67c254

Analysts' recommendations: Perspective Therapeutics, Inc.

18/09	William Blair Initiates Perspective Therapeutics With Outperform Rating	MT
19/08	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
14/08	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT
11/08	Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says	MT
18/03	UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating	MT
18/03	B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating	MT
17/03	RBC Cuts Price Target on Perspective Therapeutics to $14 From $18, Keeps Outperform, Speculative Risk	MT
19/02	Piper Sandler Initiates Coverage on Perspective Therapeutics With Overweight Rating	MT
18/11	B. Riley Adjusts Price Target on Perspective Therapeutics to $11 From $12, Maintains Buy Rating	MT
10/25/10	BTIG Research Initiates Coverage on Perspective Therapeutics With Buy Rating, $14 Price Target	MT
23/25/23	B. Riley Raises Price Target on Perspective Therapeutics to $12 From $9, Keeps Buy Rating	MT
03/25/03	RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk	MT
14/25/14	Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating	MT
13/25/13	Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating	MT
07/25/07	Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating	MT
27/25/27	RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk	MT
13/25/13	HC Wainwright Initiates Coverage on Perspective Therapeutics With Buy Rating, $10 Price Target	MT
10/25/10	Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target	MT
26/24/26	B. Riley Securities Adjusts Price Target on Perspective Therapeutics to $9 From $17, Keeps Buy Rating	MT
25/24/25	BofA Securities Downgrades Perspective Therapeutics to Neutral From Buy, Price Target is $6	MT
25/24/25	RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk	MT
13/24/13	RBC Trims Price Target on Perspective Therapeutics to $25 From $27, Keeps Outperform, Speculative Risk	MT
24/24/24	UBS Initiates Perspective Therapeutics at Buy With $20 Price Target	MT
11/24/11	Top Midday Decliners	MT
11/24/11	Wedbush Adjusts Price Target on Perspective Therapeutics to $20 From $25, Maintains Outperform Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PERSPECTIVE THERAPEUTICS, INC.					+466.16%
	WUXI APPTEC CO., LTD.					+32.97%
	LONZA GROUP AG					+14.74%
	ARGENX SE					+38.45%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+8.87%
	Average					+69.92%
	Weighted average by Cap.					+27.05%